Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
Because of the serious toxicity of intralesionally injected BCG, including high fever, local ulceration, chronic drainage, and disseminated BCG disease, 13 patients received local BCG immunotherapy by the new approach of epilesional scarification. Three patients had complete responses, four had partial responses, and six had no response. Toxic reactions were minimal compared to those reported for intralesionally given BCG.
D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000209:etiology; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D005334:Fever / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008107:Liver Diseases / Q000209:etiology; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous; D012737:Sex Factors; D012878:Skin Neoplasms / Q000628:therapy*; D012883:Skin Ulcer / Q000209:etiology
D001500:BCG Vaccine